Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trazodone - Angelini Group/Labopharm

Next Previous
Drug Profile

Trazodone - Angelini Group/Labopharm

Alternative Names: AF-1161; DDS-04A; Oleptro; Trazodone Contramid OAD; Trazodone extended release; Trazodone HCl; Trazodone OAD; Triticum AC; Trittico

Latest Information Update: 09 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angelini Group; Labopharm
  • Developer Altus Formulation Inc; Angelini Group; Lee's Pharmaceutical
  • Class Antidepressants; Erectile dysfunction therapies; Piperazines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action 5-HT2C serotonin receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Diabetic neuropathies; Insomnia
  • Preclinical Neurological disorders

Most Recent Events

  • 17 Feb 2023 Launched for Major depressive disorder in Bulgaria (PO) (before February 2023) (EudraCT2021-005007-12)
  • 17 Feb 2023 Registered for Major depressive disorder in Bulgaria (PO) (before February 2023)
  • 22 Mar 2022 Preclinical trials in Neurological disorders in Italy (unspecified route) (Angelini pipeline, March 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top